Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function

NCT02014259 ↗

Phase 1 Completed 71 enrolled Novo Nordisk A/S

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This trial is conducted in Europe. The aim of the trial is to investigate the pharmacokinetics (the exposure of the trial drug in the body), safety and tolerability of oral semaglutide in subjects with various degrees of impaired renal function compared to subjects with normal renal function.

Timeline

Start: 2013-12-11
Primary completion: 2014-10-24
Completion: 2014-10-24

Publications

Results Granhall C, Sondergaard FL, Thomsen M, Anderson TW. Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects with Renal Impairment. Clin Pharmacokinet. 2018 Dec;57(12):1571-1580. doi: 10.1007/s40262-018-0649-2.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Semaglutide	Peptide	10 mg	Oral

Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function

Summary

Timeline

Publications

Drugs

Indications